Here are seven oncology and hematology drugs approved by the FDA in September:
- Selpercatinib for patients aged 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation.
- Osimertinib for adult patients with locally advanced, unresectable (stage 3) non-small cell lung cancer with the following conditions:
- Disease has not progressed from platinum-based chemoradiation therapy
- Tumors have EGFR exon 19 deletions or exon 21 L858R mutations
- Isatuximab-irfc, with bortezomib, lenalidomide and dexamethasone, for adults newly diagnosed with multiple myeloma and ineligible for autologous stem cell transplant
- Amivantamab-vmjw, with carboplatin and pemetrexed, for adult patients with locally advanced or metastatic non-small cell lung cancer with the following conditions:
- Epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations
- Disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor
- Embrolizumab, with pemetrexed and platinum chemotherapy, as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma
- Ribociclib, with an aromatase inhibitor, for adjuvant treatment of adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative stage 2 and 3 early breast cancer at high risk of recurrence.
- The FDA also approved a ribociclib and letrozole co-pack for the same indication
- Atezolizumab and hyaluronidase-tqjs for subcutaneous injection, for all adult indications, as the intravenous formulation of atezolizumab including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma and alveolar soft part sarcoma.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
